A carregar...
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemotherapy. However, some patients experience treatment resista...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6352369/ https://ncbi.nlm.nih.gov/pubmed/30696487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0509-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|